Donald Northfelt, MD
Hematology & Oncology · Phoenix, AZNPI 1316922008
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $460 of the $546 with a category attached, or 84.3%. 11 manufacturers reported payments, led by Stemline Therapeutics Inc. at 28.3% of the total. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 13 payments — averaging $42.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$155
- Apellis Pharmaceuticals, Inc.$140
- Lilly USA, LLC$74
- Genentech USA, Inc.$37
- Beone Medicines USA, Inc.$32
- AVEO Pharmaceuticals, Inc.$31
- plus $77 from 5 others
Across 101 payments — averaging $16,963 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$723K
- Merck$574K
- Genentech, Inc.$117K
- Roche Products Limited$79K
- Regeneron$69K
- GSK$50K
- plus $101K from 5 others
What the payments were for
- Food & beverage$46084%
- Education$8616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 2 | $155 |
| Apellis Pharmaceuticals, Inc. | 1 | $140 |
| Lilly USA, LLC | 1 | $74 |
| Genentech USA, Inc. | 2 | $37 |
| Beone Medicines USA, Inc. | 1 | $32 |
| AVEO Pharmaceuticals, Inc. | 1 | $31 |
| Merck | 1 | $20 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| AstraZeneca | 1 | $15 |
| Gilead | 1 | $12 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orserdu$124
How this compares
$546 in reported general payments places this provider in the 20th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 44 | $691,896 |
| TasignaNilotinib Hcl | 11 | $114,445 |
| MonjuviTafasitamab-Cxix | 11 | $62,111 |
| Exemestane | 35 | $2,134 |
| Letrozole | 61 | $1,183 |
| Anastrozole | 50 | $1,027 |
| Prochlorperazine Maleate | 26 | $208 |
| FamotidineFamotidine In Nacl,iso-Osm/Pf | 12 | $95 |
| Ondansetron Hcl | 21 | $80 |
| Dexamethasone | 12 | $76 |
| Azathioprine | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Phoenix
- Javier MunozPhoenix$638K
- Mazen KhattabPhoenix$186K
- Robert GalamagaPhoenix$168K
- Panayiotis SavvidesPhoenix$153K
- Robert YooPhoenix$44K
- Sunil TulpulePhoenix$36K
- Tania CortasPhoenix$33K
- Mahesh SeetharamPhoenix$30K
- Boo Ghee LowPhoenix$25K
- Sujith KalmadiChandler$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.